Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

Yoshihiko Tomita, Sei Naito, Naoto Sassa, Atsushi Takahashi, Tsunenori Kondo, Takuya Koie, Wataru Obara, Yasuyuki Kobayashi, Jun Teishima, Masayuki Takahashi, Hideyasu Matsuyama, Takeshi Ueda, Kenya Yamaguchi, Takeshi Kishida, Ryoichi Shiroki, Takashi Saika, Nobuo Shinohara, Mototsugu Oya, Hiro omi Kanayama

研究成果: Article査読

1 被引用数 (Scopus)

抄録

The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).

本文言語English
ページ(範囲)e374-e385
ジャーナルClinical Genitourinary Cancer
18
4
DOI
出版ステータスPublished - 08-2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

フィンガープリント 「Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル